Back to results
US 11,306,136 B2Granted
Selective IL-6-trans-signalling inhibitor compositions
AssigneeFerring B.V.
InventorsIan Cottingham, Daniel Plaksin, Jérémy Duboeuf
Life of this patent
Estimating the term…
Abstract
A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
Claims13
A method of treating a subject suffering from or susceptible to a chronic inflammatory disease or a chronic IL-6-mediated condition, the method comprising:
- administering to a subject a composition comprising a polypeptide dimer comprising two gp130-Fc monomers comprising an amino acid sequence at least 95% identical to SEQ ID NO:
- 1,
- wherein the composition comprises no greater than 6 mol % of galactose-alpha-1,3-galactose per mole polypeptide;
- and
- wherein the chronic inflammatory disease or chronic IL-6-mediated condition is inflammatory bowel disease.
2 more elements
A method of treating a chronic inflammatory disease or a chronic IL-6-mediated condition in a subject comprising:
- administering to a subject in need thereof a composition comprising a polypeptide dimer comprising two gp130-Fc monomers comprising the amino acid sequence at least 95% identical to SEQ ID NO:
- 1, wherein the monomers comprise the gp130 D6 domain corresponding to the amino acids at positions 585-595 of the amino acid sequence of SEQ ID NO:1, an Fc domain hinge region comprising the amino acids at positions 609-612 of the amino acid sequence of SEQ ID NO:1, and the monomers do not comprise a linker between the gp130 D6 domain and the Fc domain hinge region, wherein:
- the composition comprises no greater than 6 mol % of galactose-alpha-1,3-galactose per mole polypeptide.
Dependencies are inferred from the claim text.